Proliferation. Regul Pept 2007, 143:109-117. 100. Sharif N, Gendron L, Wowchuk J, Sarret > 자유게시판

Proliferation. Regul Pept 2007, 143:109-117. one hundred. Sharif N, Gendron L, Wowchuk J, Sarret P, Mazella J, Beaudet A, Stroh T: Coexpression of somatostatin receptor subtype five impacts internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007, 148:2095-2105. 101. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U: Heterooligomerization of human dopamine receptor two and somatostatin receptor two. Coimmunoprecipitation and fluorescence resonance power transfer investigation. Cell Signal 2007, 19:2304-2316. 102. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and remedy of neuroendocrine tumours. European Journal of Endocrinology 2004, 151:15-27. 103. Sunlight LC, Luo J, Mackey VL, Fuselier JA, Coy DH: Outcomes of camptothecin on tumor cell proliferation and angiogenesis when coupled to some bombesin104.one hundred and five.106.107.108.109.a hundred and ten.111.112. 113.114.analog applied as being a qualified shipping vector. Anticancer Medicine 2007, eighteen:341-348. Fj ling M, Andersson P, Forssell-Aronsson E, Gr arsd tir J, Johansson V, Tisell LE, W gberg B, Nilsson O, Berg G, Michanek A, Lindstedt G, Ahlman H: Systemic radionuclide treatment applying indium-111-DTPA-DPhe1-octreotide in midgut carcinoid syndrome. J Nucl Med 1996, 37:1519-1521. Heppeler A, Froidevaux S, Eberle AN, Maecke HR: Receptor concentrating on for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000, seven:971-994. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J: The clinical price of (90Y-DOTA)-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) during the treatment method of neuroendocrine tumours: a medical period II research. Ann Oncol 2001, twelve:941-945. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP: Neuroendocrine Tumors. Peptide receptor radionuclide treatment. Best Pract Res Clin Endocrinol Metab 2007, 21:111-29. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP: Combination radionuclide treatment using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005, forty six:13S-17S. Oberg K, Eriksson B: Nuclear medicine while in the detection, staging and treatment method of gastrointestinal carcinoid tumours. Most effective Pract Res Clin Endocrinol Metab 2005, 19:265-276. Chan JA, Kulke MK: Rising therapies for the treatment of patients with innovative neuroendocrine tumors. Skilled Opin Emerg Prescription drugs 2007, twelve:253-270. Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C: Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk amongst NF-kappaB and JNK pathways. Mobile Demise Vary 2007, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/16989806 fourteen:197-208. Jensen RT: Gastrinomas: developments in diagnosis and management. Neuroendocrinology 2004, eighty:23-27. Carrere N, Vernejoul F, Atazanavir Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscail L, Cordelier P: Characterization in the bystander result of somatostatin receptor sst2 soon after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther 2005, 16:1175-1193. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, Susini C, Buscail L: Antitumor effect of in vivo somatostatin receptor subtype two gene transfer in primary and metastatic pancreatic most cancers types. Most cancers Res 2002, sixty two:6124-6131.doi:10.1186/1756-9966-29-19 Cite this short article as: Appetecchia and Baldelli: Somatostatin analogues in the procedure of gastroenteropancreatic neuroendocrine tumours, recent factors and new perspectives. Journal of Experimental Scientific Canc.